QIAGEN fully acquires NeuMoDx Molecular, Inc., rounding out portfolio of PCR-based diagnostic automation systems

Author's Avatar
Sep 18, 2020
Article's Main Image

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the acquisition of the remaining 80.1% of diagnostics instruments company NeuMoDx Molecular, Inc. for $248 million in cash. The move rounds out QIAGEN’s portfolio of automated molecular testing solutions based on the proven PCR technology.